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Chromosomal microarray (CMA) is increasingly utilized for genetic testing of individuals with unexplained developmental delay/intel-
lectual disability (DD/ID), autism spectrum disorders (ASD), or multiple congenital anomalies (MCA). Performing CMA and G-banded
karyotyping on every patient substantially increases the total cost of genetic testing. The International Standard Cytogenomic Array
(ISCA) Consortium held two international workshops and conducted a literature review of 33 studies, including 21,698 patients tested
by CMA. We provide an evidence-based summary of clinical cytogenetic testing comparing CMA to G-banded karyotyping with respect
to technical advantages and limitations, diagnostic yield for various types of chromosomal aberrations, and issues that affect test inter-
pretation. CMA offers a much higher diagnostic yield (15%–20%) for genetic testing of individuals with unexplained DD/ID, ASD, or
MCA than a G-banded karyotype (~3%, excluding Down syndrome and other recognizable chromosomal syndromes), primarily because
of its higher sensitivity for submicroscopic deletions and duplications. Truly balanced rearrangements and low-level mosaicism are
generally not detectable by arrays, but these are relatively infrequent causes of abnormal phenotypes in this population (<1%). Available
evidence strongly supports the use of CMA in place of G-banded karyotyping as the ﬁrst-tier cytogenetic diagnostic test for patients with
DD/ID, ASD, or MCA. G-banded karyotype analysis should be reserved for patients with obvious chromosomal syndromes (e.g., Down
syndrome), a family history of chromosomal rearrangement, or a history of multiple miscarriages.Introduction
Scope and Purpose
Clinical genetic testing, including chromosome analysis, is
a standard practice for patients with diagnoses including
unexplained developmental delay/intellectual disability
(DD/ID), autism spectrum disorders (ASD), and multiple
congenital anomalies (MCA). These categories of disorders
account for the largest proportion of cytogenetic testing
because of their high prevalence in the population. The
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lack sufﬁcient speciﬁc history or features from physical
examination to suggest a speciﬁc genetic (or non-genetic)
cause. Published guidelines for testing such patients have
emphasized (1) testing for chromosomal abnormalities
by G-banded karyotyping and (2) testing for common
single-gene disorders, such as fragile X syndrome.4
Microarray-based genomic copy-number analysis is now
a commonly ordered clinical genetic test for this patient
population and is offered under various names, such
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karyotyping.’’5–10 CMA, as used here, encompasses all
types of array-based genomic copy number analyses,
including array-based comparative genomic hybridization
(aCGH) and single nucleotide polymorphism (SNP) arrays.
G-banded karyotyping allows a cytogeneticist to visualize
and analyze chromosomes for chromosomal rearrange-
ments, including genomic gains and losses. CMA performs
a similar function, but at a much higher resolution for
genomic imbalances. G-banded karyotyping has been the
standard ﬁrst-tier test for detection of genetic imbalance
in this population for more than 35 years, whereas CMA
is not yet standard in all clinical settings.Clinical Interpretation of CMA Results
Although clinical genetic laboratories are familiar with
recurrent copy-number changes mediated by segmental
duplication architecture, population studies suggest that
the vast majority of copy-number variation is not recur-
rent.11 Determining the clinical signiﬁcance of variants
identiﬁed by CMA can be challenging. Although CMA
offers the sensitivity of high-resolution genome-wide
detection of clinically signiﬁcant copy-number variants
(CNVs), the additional challenge of interpreting variants
of uncertain clinical signiﬁcance (VOUS), the preferred
terminology based on a recent study of variant termi-
nology, can impose a burden on clinicians and laborato-
ries.12 Furthermore, recent efforts to evaluate reporting of
CNVs among clinical laboratories indicates variability of
interpretation.13
Lack of uniform guidelines for the expected clinical yield
of CMA, in terms of resolution and coverage (i.e., whole
genome or locus speciﬁc), impedes standardization of
clinical practice for CMA testing. CMA is currently per-
formed in many different laboratories with different tech-
nology platforms and different array design and content.
Uniform interpretation of results is an equally formidable
challenge to standardization. Most clinical laboratories
maintain internal databases of pathogenic and benign
CNVs, but they might not agree on interpretations.13
Although College of American Pathology (CAP) proﬁ-
ciency testing is now available for CMA, there is not yet
an openly accessible centralized resource for comparing
clinical interpretations for thousands of possible variants
among dozens of laboratories performing this testing.
These problems can be addressed through more uniform
array content, a rational approach to variant interpreta-
tion, and increased data sharing among laboratories and
clinicians. Sharing of information across laboratories will
provide the most beneﬁt to laboratories, clinicians, and—
ultimately and most importantly—patients.
We evaluated the beneﬁts and limitations of CMA, as
compared to G-banded karyotyping, for detecting patho-
genic genomic imbalances in patients with DD/ID, ASD,
and/or MCA. Recommendations for CMA use and stan-
dardization as a ﬁrst-tier genetic test in this patient popula-
tion are provided.750 The American Journal of Human Genetics 86, 749–764, May 14,Subjects and Methods
Assembly and Focus of the ISCA Consortium
The International StandardCytogenomicArray (ISCA)Consortium
is an independent group assembled, through voluntary participa-
tion of an international group of experts in this ﬁeld, to address
mutual concerns about standardization and collaboration for clin-
icalCMAtesting.The ISCAheld two internationalworkshops spon-
sored by a grant from the American College of Medical Genetics
(ACMG) Foundation and Luminex to explore and implement
improvements in CMA testing. The workshops included ten clini-
cians (clinical geneticists or genetic counselors (D.T.M., M.P.A.,
L.G.B., C.J.E., W.A.F., J.M.F., A.H., L.J., I.D.K., and D.J.W.); 17 clinical
laboratory geneticists (D.T.M., S.A., A.R.B., J.A.C., J.M.F., L.J., K.K.,
C.L., C.R., N.B.S., D.J.S., J.H.T., E.C.T., J.R.V., M.S.W., C.L.M, and
D.H.L.); and nine genome scientists and bioinformaticians (N.P.C.,
D.M.C., E.E.E., L.F., E.B.K., R.M.K., C.L., J.M.O., and S.W.S.).
Thegoalsof the ISCAConsortiumare analogous to thegoals of the
Newborn Screening (NBS) Expert Group convened by the ACMG
in 2006 to address the lack of uniformity in state-based NBS
programs.14,15 For many years, each state made independent deci-
sions regarding which diseases to include in NBS, leading to a wide
range of diseases tested by different states. An expert panel devel-
oped an evidence-based recommendation for a uniform, core panel
of 29 well-deﬁned disorders. Testing for the vast majority of these
core conditions has now been implemented or mandated (but not
yet implemented) in all 50 states.16
The ISCA Consortium is focused on the clinical application of
CMA as opposed to laboratory technical guidelines. This report
is intended as a review of available data to determine whether
CMA should be adopted as a ﬁrst-tier test before routine G-banded
karyotyping in this patient population (deﬁned below). We re-
viewed previously published clinical-practice guidelines9,17 and
laboratory guidelines18 for clinical CMA testing. CMA is a high-
complexity assay with many technical considerations beyond
the scope of this discussion. Suggested guidelines about specimen
requirements, DNA preparation, labeling, analysis algorithms, and
assay validation are beyond the scope of this discussion but have
been outlined elsewhere.9,18
Patient Population
The analysis and recommendations in this manuscript are focused
solely on CMA for constitutional abnormalities in postnatal
testing of patients with DD/ID, ASD, or MCA. These analyses
and conclusions are not necessarily applicable to other CMA appli-
cations, such as prenatal testing, hematological malignancies, or
other forms of cancer. Although the ISCA Consortium recognizes
the potential for CMA to play a role in prenatal diagnosis, current
evidence is not sufﬁcient to allow recommendations regarding
prenatal CMA, and traditional cytogenetic methods, such as G-
banded karyotyping and ﬂuorescence in situ hybridization (FISH),
are still the standard for prenatal diagnosis, as supported in a recent
American College of Obstetrics and Gynecology (ACOG) State-
ment.19 Multicenter studies making a direct comparison of the
performance of CMA to conventional cytogenetic analysis in a
prenatal setting are currently underway.Systematic Literature Review
We conducted a systematic literature review focused on clinical
CMA by searching the PubMed database of the National Center
for Biotechnology Information (NCBI) and using the following2010
Table 1. Assessment of Pathogenicity of a CNVa
Primary Criteria
Indicates CNV Is Probably
Pathogenic Benign
1. a. Identical CNV inherited
from a healthy parentb
U
b. Expanded or altered CNV
inherited from a parent
U
c. Identical CNV inherited
from an affected parent
U
2. a. Similar to a CNV in
a healthy relative
U
b. Similar to a CNV in an
affected relative
U
3. CNV is completely contained
within genomic imbalance
deﬁned by a high-resolution
Ucontrolled vocabulary MeSH terms: (Microarray Analysis) AND
((chromosomal disorders) OR (chromosomal aberration)) AND
((mental retardation) OR (developmental disabilities) OR (Autism)
OR (congenital abnormalities)). We included case series or cohort
studies that were posted to PubMed prior to April 15, 2009 and
that included either bacterial artiﬁcial chromosome (BAC) or
oligonucleotide arrays. We considered studies with (1) a clear
description of the patient population, including patient selection
criteria; (2) a description of the CMA platform and resolution; and
(3) a description of the process for interpretation of CMA results.
We also included published studies that were not necessarily
identiﬁed by this combination of search terms if they met the
aforementioned criteria. We excluded studies that presented
only validation samples for new techniques or platforms or were
focused on a particular medical condition or syndrome (e.g.,
only one type of congenital anomaly). We identiﬁed 33 original
reports (not reviews), including 21,698 patients for expert review
and discussion by ISCA Consortium workshop participants.
technology in a CNV database
of healthy individuals
4. CNV overlaps a genomic
imbalance deﬁned by a high-
resolution technology in
a CNV database for patients
with ID/DD, ASD, or MCA
U
5. CNV overlaps genomic
coordinates for a known
genomic-imbalance
syndrome (i.e., previously
published or well-recognized
deletion or duplication
syndrome)
UClassiﬁcation of CMAVariants
Typical strategies for interpreting pathogenic or benign status for
CNVs (Table 1) have been outlined elsewhere,9,20,21 In general,
copy-number variants are assigned the following interpretations
(1) abnormal (e.g., well-established syndromes, de novo variants,
and large changes); (2) VOUS; (3) likely benign (e.g., not previously
reported but inherited froma healthy parent). Diagnostic yieldwas
deﬁned as the number of patients with abnormal variants divided
by the total number of patients tested and was derived directly
from each original study. Data were not systematically collected
on the number of VOUS in each study.
6. CNV contains morbid OMIM
genesc
U
7. a. CNV is gene rich U
b. CNV is gene poor U
General Findingsd
1. a. CNV is a deletion U
b. CNV is a homozygous
deletion
U
2. a. CNV is a duplication (no
known dosage-sensitive
genes)
U
b. CNV is an ampliﬁcation
(greater than 1 copy gain)
U
3. CNV is devoid of known
regulatory elements
U
aSingle copy-number change.
bAn inherited deletion from an unaffected parent could harbor an OMIM
morbid gene that is recessive and could be pathogenic in conjunction with
a point mutation on the trans allele inherited from the other parent.
cCNV should produce the same type of mutation that is known to cause the
OMIM disease (e.g., a heterozygous deletion can cause an OMIM disease
that is usually caused by a heterozygous inactivating mutation) and the pheno-
type produced should be that expected for the OMIM disease.
dExceptions to each case have been seen.Development of a CNVDatabase through the National
Institutes of Health
The ISCA Consortium has initiated a new database for CNV and
phenotype data generated from clinical CMA laboratories as
a project within dbGaP (Database of Genotype and Phenotype at
NCBI). This database is capable of receiving and managing raw
data and normalized data ﬁles from all current CMA platforms,
including both copy-number and SNP arrays. The common
denominator for displaying and comparing data from different
labs and platforms will be the use of genome sequence coordi-
nates, based on the UCSC Genome Browser, for deﬁning the start
and stop points for any copy-number imbalance (loss or gain). To
minimize barriers to data contribution by clinical laboratories and
maximize the empirical data available on CNVs from this patient
population, an opt-out mechanism to notify patients that their
deidentiﬁed data will be contributed to the database has been
developed and approved by the central institutional review board
(IRB) at the National Institutes of Health and the IRBs at individual
contributing centers. All participating centers will also be strongly
encouraged to obtain a full informed consent and submit qualiﬁed
cases to DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources) as well.
The opt-out mechanism is a relatively new concept that allows
deidentiﬁed data collected as part of clinical testing to be used
for multiple reasons, including improving the accuracy and
quality of test results, test validation, educational purposes, or
research. Patients are notiﬁed of the opt-out mechanism through
various avenues, such as test requisition forms, clinical laboratory
reports, and laboratory websites. It is also the responsibility of the
ordering physician or other downstream providers who reviewThe Amerequisitions and reports containing the opt-out language to
inform patients how samples are managed and data are used and
that they can opt out of inclusion at any time. Because this mech-
anism is a growing area that will be of great use to the clinical and
research communities and will ultimately improve clinical care,rican Journal of Human Genetics 86, 749–764, May 14, 2010 751
Table 2. Summary of Clinical CMA Studies on 21,698 Subjects
Author Location Patients Phenotype Controls Array Type Resolution
Diagnostic
Yield
Vissers et al.
(2003)22
Netherlands
and U.S.
20 ID, DF 4 (2M, 2F) BAC Whole genome
(1.0 Mb)
10.0%
Shaw-Smith
et al. (2004)23
U.K., France 50 ID (moderate
to severe)
Pooled DNA
(20M, 20F)
BAC Whole genome
(1.0 Mb)
14.0%
de Vries et al.
(2005)6
Netherlands 100 ID 72 parents of
probands
BAC Whole genome
(50 kb)
10.0%
Schoumans
et al. (2005)24
Sweden 41 ID (mild to
severe)
Pooled DNA
(10 subjects)
BAC Whole genome
(1.3 Mb)
9.8%
Tyson et al.
(2005)25
Canada 22 ID, DF Pooled normal
of four to six
males or females
(Promega)
BAC Whole genome
(1.3 Mb)
13.7%
Wong et al. (2005)26 U.S. 102 ID Normal controls BAC Telomere 18.6%
Ballif et al. (2006)27 U.S. 3600 ID, DD BAC Targeted 5.1%
Friedman et al.
(2006)28
Canada 100 ID 8 unaffected siblings SNP Oligo
(Affy 100k)
Whole genome
(30 kb)
11.0%
Krepischi-Santos
et al. (2006)29
Brazil 95 ID, DF,
MCA
100 control
observations for each
chromosome pair
BAC Whole genome
(1.0 Mb)
16.8%
Menten et al.
(2006)30
Belgium 140 ID, MCA Other patient
samples in cohort
BAC Whole genome
(1.0 Mb)
13.6%
Ming et al.
(2006)31
U.S. 10 MCA 128 (42 Caucasian,
42 African-American,
20 Asian, 20 NIGMS)
SNP Oligo
(Affy 100k)
Whole genome
(30 kb)
20.0%
Miyake et al.
(2006)32
Japan 30 ID, MCA 2 negative (1M, 1F),
1 positive
BAC Targeted (1.4 Mb) 16.7%
Rosenberg et al.
(2006)33
Netherlands,
Brazil, U.K.
81 ID (Mild to
severe), DF
100 control
observations for each
chromosome pair
BAC Whole genome
(1.0 Mb)
16.0%
Sharp et al.
(2006)34
U.K., U.S. 290 ID þ/ DF;
þ/ MCA
316 controls from
various ethnicities
BAC Targeted 5.5%
Shaffer et al.
(2006)35
U.S. 1500 Various
indications
Opposite gender
control
BAC Targeted 5.6%
Aradhya et al.
I(2007)36
U.S. 20
(12M, 8F)
ID or DD
þ/ DF;
þ/ MCA,
þ/ GR
Normal male or
female (Promega)
Oligo
(Agilent 44k)
Whole genome
(70 kb)
35.0%
Baris et al.
(2007)37
U.S. 234 ID or DD,
DF, MCA
50 normal controls
(25M, 25F) and
36 patients with
abnormal
chromosome testing
BAC Targeted 5.6%
Engels et al.
(2007)38
Germany 60 ID Pooled DNA
(10M, 10F)
BAC Whole genome
and Targeted
(0.5 Mb)
10.0%
Fan et al.
(2007)39
U.S. 100 ID or DD 7M, 7F gender
matched
Oligo
(Agilent 44k)
Whole genome
(35 kb)
15.0%
Hoyer et al.
(2007)10
Germany 104 ID Not speciﬁed SNP Oligo
(Affy 100k)
Whole genome
(30 kb)
9.6%
Lu et al. (2007)40 U.S. 2513 ID or DD, DF,
MCA, ASD
Normal (1M, 1F) BAC Targeted 7.0%
Newman
et al. (2007)41
U.K. 36 DD, LD, DF Not speciﬁed BAC Whole genome
(1.0 Mb)
13.8%
Shaffer et al.
(2007)42
U.S. and
‘‘abroad‘‘
8789 ID or DD,
MCA
Normal (1M) BAC Targeted 6.9%
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Table 2. Continued
Author Location Patients Phenotype Controls Array Type Resolution
Diagnostic
Yield
Shen et al.
(2007)43
U.S. 211 ID or DD,
MCA, MCA
Normal (1M, 1F) Oligo (Agilent) Targeted (35 kb
in target regions)
7.6%
Thuresson
et al. (2007)44
Sweden 48 ID, DF, MCA 8M, 8F gender
matched
BAC 1 Whole genome
(1.0 Mb)
6.3%
Wagenstaller
et al. (2007)45
Germany 67 ID (mild to
severe)
44 unaffected parents
and 4 children with
known translocations
SNP Oligo
(Affy 100k)
Whole genome
(30 kb)
16.4%
Aston et al.
(2008)46
U.S. 1075 ID, DD,
DF, MCA
Normal control
of the opposite
gender (Promega)
BAC Whole genome
(1.3 Mb)
5.3%
Baldwin et al.
(2008)47
U.S. 211 ID, DD, DF,
MCA, ASD
Normal control
of the opposite
gender (Promega)
Oligo (custom
Agilent 44k)
Whole genome
and Targeted
(75 kb)
15.6%
Pickering et al.
(2008)48
U.S. 1176 ID or DD Normal (1M, 1F) BAC Targeted (n ¼ 822)
and whole genome
(1 Mb; n ¼ 354)
7.8%
Shevell et al.
(2008)49
Canada 94 ID, DD Not speciﬁed BAC Targeted 6.4%
Xiang et al.
(2008)50
U.S. 50 ID, DD Gender mismatched Oligo
(Agilent 44k)
Whole genome
(35 kb)
18.0%
Nowakowska
et al. (2008)51
U.S. 91 ID, DF Normal (1M, 1F) BAC Targeted 11.8%
Lu et al. (2008)52 U.S. 638 MCA Normal (1M, 1F) BAC (n ¼ 372)
and Oligo
(n ¼ 266)
Targeted with
backbone
17.1%
ASD ¼ autism spectrum disorders; BAC¼ bacterial artificial chromosome; DD¼ developmental delay; DF¼ dysmorphic features; ID¼ intellectual disability; LD¼
learning disabilities; MCA ¼multiple congenital anomalies. Where an array is indicated as ‘‘targeted,’’ the resolution of regions outside the target area (e.g., back-
bone coverage) is not specified.educational materials are also being developed for patients and
healthcare providers. Our current NIH-funded grant supports an
education and ethics working group comprised of experienced
genetic counselors and clinicians who will continually address
these important issues.
Working groups have been established to determine standard
data formats and vocabularies for genotypic and phenotypic data,
as well as to make recommendations for standard interpretation
guidelines for CMA results. An expert curation process is being
established so that discrepancies within the data can be identiﬁed
and resolved, and public data releases are planned on a quarterly
basis. These will be available to major genomics resources (e.g.,
UCSC Genome Browser, ENSEMBL, DECIPHER, Database of
Genomic Variants (DGV), etc.) via the Database of Structural Vari-
ation (dbVar), but also to individual laboratories and commercial
vendors for CMA software and database software products.Results
Diagnostic Yield of CMA Is Greater
than that of G-Banded Karyotyping
We reviewed 33 studies, together including 21,698 patients
tested by CMA (Table 2). CMA detected pathogenic
genomic imbalances with an average diagnostic yield of
12.2% across all studies in this patient population, about
10% more than G-banded karyotyping alone. We also re-The Ameviewed studies related to potential limitations of CMA as
a clinical test, especially with regard to detection of
VOUS, balanced translocations, and low-level mosaicism.
Our results also include an overview of the CNV Database
developed through the ISCA Consortium.
Diagnostic yield has improved as the resolution of cyto-
genetic testing for patients with developmental disabilities
has evolved. G-banded karyotyping can sometimes detect
genomic imbalances as small as 3 Mb, but it can often
miss genomic imbalances in the 5–10 Mb range, depend-
ing on the genomic region involved and/or conditions of
the assay (Figure 1). If patients with Down syndrome
(MIM 190685) are excluded, G-banded karyotyping of
patients with ID has typically identiﬁed abnormalities in
fewer than 3% of individuals.1,53–56 Karyotyping is also
limited because it is based on the subjective assessment
of gains and losses and is prone to considerable interper-
sonal and interlaboratory variation in detection rates.
The addition of subtelomeric ﬂuorescence in situ hybrid-
ization (FISH) for identifying submicroscopic deletions and
duplications of genomic regions proximal to the telomeres
has been shown to almost double the diagnostic yield. In
the largest analysis of subtelomeric FISH testing, presumed
pathogenic changes were found in 2.6% of 11,688 unse-
lected cases,57 and a recent review of another 7,000 cases
found subtelomeric rearrangements in 2.4% of the patientsrican Journal of Human Genetics 86, 749–764, May 14, 2010 753
Figure 1. Examples of Genomic Imbalances Detected by a CMA but Not by G-Banded Karyotyping
(A) A 10.9 Mb deletion, including more than 60 genes. The deletion includes the Williams-Beuren syndrome region at chromosome
region 7q11 but extends beyond the typical breakpoints for this syndrome. The arrow is pointing to the deleted chromosome that
was observed by retrospective analysis of G-banded slides.
(B) A 7.2 Mb duplication on the long arm of chromosome 11. Again, the arrow is pointing to the chromosome that has the duplication
shown by the darker G-positive band.studied.58 Most FISH assays used in a clinical cytogenetic
setting detect submicroscopic changes in the range of
100 kb or larger. BAC-based arrays can detect genomic im-
balances 100 kb and larger, depending on probe coverage.
The increased yield of clinical genetic diagnoses with
CMA parallels the evolution of array designs (Figure 2).
Early clinical CMA tests included BAC clones and targeted
subtelomeric and pericentromeric regions, ‘‘known’’ recur-
rent microdeletion and microduplication syndromes, or
whole-genome coverage with clones at ~1 Mb genomic
intervals (Figure 2),59,60 and diagnostic yields were 7%–
11% for children with normal G-banded cytogenetic
analysis.22–24,33,35,61–63 Subsequent versions of clinical
CMA tests included additional probes, so-called genomic
‘‘backbone’’ coverage, allowing for the detection of patho-
genic genomic imbalances outside of the well-described
critical regions for microdeletion and microduplication
syndromes. Rapid increases in the availability of genome-
wide arrays with density sufﬁcient to allow detection
of copy-number changes of ~100 kb throughout the
genome increased diagnostic yields to between 11% and
15%28,10,39 based on studies of DD/ID patients who had
normal G-banded cytogenetic analysis; these yields are
far higher than what was obtained via traditional cytoge-
netic methods.754 The American Journal of Human Genetics 86, 749–764, May 14,CMA Platform Comparison
Most commercial and academic laboratories have now
converted to oligonucleotide- or SNP-based arrays. Some
clinical laboratories use oligonucleotide-based arrays that
emulate the coverage of earlier versions of BAC-based
arrays. Advantages of oligonucleotide-based arrays include
more ﬂexibility in terms of probe selection, thus facili-
tating higher probe density and customization of array
content. Arrays designed speciﬁcally for copy-number
analysis use longer oligonucleotide probes (~60-mer),
which have been shown to provide better signal-to-noise
ratios (SNRs) than the shorter oligonucleotide probes
(~22-mer) used in some SNP-detecting array platforms.64
Longer oligonucleotides (50-mer) on some SNP-detecting
arrays result in a better signal-to-noise ratio than short
oligonucleotide SNP arrays. Also, SNP-detecting arrays
now typically include a mixture of SNP and copy-number
probes to address this issue.
In general, high speciﬁcity can be achieved by current
BAC or oligonucleotide arrays, including SNP arrays, de-
pending on coverage. BAC-based arrays employ large-insert
genomic clones of 100–150 kb, and accurate copy-number
determination can be made for individual clones. Single
oligonucleotide probes do not provide accurate determina-
tion of copy number, and multiple consecutive probes2010
Figure 2. Evolution of a Constitutional CMA Design
(A) Early versions of array-based Comparative Genomic Hybridiza-
tion (aCGH) platforms used for constitutional cytogenetic testing
targeted the subtelomeric and pericentromeric regions and
deﬁned microdeletion and microduplication syndromes.61,62
(B) Later, more extensive coverage was added at the subtelomeric
and pericentromeric regions and included additional probes out-
side the targeted regions; this is so-called ‘‘backbone’’ coverage.
(C) Higher-density backbone coverage or high-density genome-
wide arrays provide essentially whole-genome coverage, yielding
even higher detection rates.47indicating the same copy-number change are required
for accurately determining a gain or loss. The number of
consecutive probes required may vary between arrays of
long-oligonucleotide probes and SNP probes, and SNP
arrays typically require more consecutive probes to achieve
comparable speciﬁcity.
SNP arrays have the advantage of also detecting long
stretches of homozygosity, which might represent unipa-
rental disomy (UPD) or consanguinity not suspected on
the basis of clinical history. However, routine CMA anal-
ysis with SNP-based platforms will detect heterodisomic
UPD only in that portion of cases where there are blocks
of isodisomy. UPD occurring by trisomy rescue usually
contains blocks of heterodisomy and isodisomy but can
result in complete heterodisomy.
Arrays based entirely on probes for SNPs are biased to
certain genomic segments containing common SNPs. One
earlier SNP-detecting array could detect only ~26% of the
CNVs that were detected by fosmid end sequencemapping
strategies.65 For this reason,newer SNP-detecting arrays also
contain nonpolymorphic oligonucleotide probes exclu-
sively designed for copy-number detection to providemore
robust and uniform coverage. Overall, with sufﬁciently
dense probe coverage, all current array platforms are able
to provide sufﬁcient sensitivity for clinical CMA testing.
Recommendations for CMA Coverage and Resolution
The clinically effective resolution of CMA represents a
balance between sensitivity and speciﬁcity. Analytical
sensitivity is primarily inﬂuenced by probe coverage, reso-
lution, and genomic spacingof probes selected for the array.
For CMA to identify genomic imbalances at a higher resolu-
tion than a conventional G-banded karyotype, the array
must consistently detect clinically signiﬁcant genomicThe Ameimbalances smaller than 5 Mb. Clinical sensitivity of CMA
should be considered in relation to G-banded karyotyping
and not in comparison to gene-speciﬁc molecular-based
assays for Mendelian disorders.
Available oligonucleotide platforms can now detect
genomic imbalances as small as 500 bp,66 permitting the
detection of genomic copy-number changes as small as 10–
20kb inmanyregionsof thegenome.Clinical arraysare typi-
cally designed to detect imbalances of 20–50 kb in targeted
regions (e.g., within known Mendelian genes) and imbal-
ances of 100–250 kb in nontargeted (backbone) regions of
the genome. The ability to identify smaller deletions allows
diagnosis of diseases caused by as few as one haploinsufﬁ-
cient gene, which increases the diagnostic capability of
this testing.However, this level of resolution isnotnecessary
as a genome-wide clinical test of genomic imbalance.
Most current clinical CMA platforms can detect copy-
number changes with a lower limit of resolution of
~400 kb throughout the genome, representing aR10-fold
improvement in resolution in comparison to G-banded
karyotyping. This level of resolution will provide a broad
genomic survey and reliably identify all known recurrent
microdeletion and microduplication syndromes medi-
ated by segmental duplication architecture and most
nonrecurrent pathogenic imbalances that are unequivo-
cally pathogenic. The smallest known recurrent microdele-
tion syndromes, such as deletions at 17q21.31 (MIM
610443)34,67–69 and 16p11.2 (MIM 611913),70–72 are ~500
kb or larger.
Although copy-number alterations smaller than ~400 kb
may certainly be pathogenic and smaller disease-causing
CNVs are likely to be identiﬁed on an ongoing basis,
higher-resolution CMA detects an increasing proportion
of benign CNVs. Decisions about clinically interpretable,
effective resolution for CMA should therefore also consider
empiric data about size distribution of CNVs in the human
genome. Research-based tiling arrays used on HapMap
samples (consideredhealthy individuals) revealed amedian
size for presumably benign CNVs of ~200 kb and showed
that 90%–95% of these CNVs are less than 500 kb.11,73
More recent data with higher-density arrays suggest that
many more ‘‘small’’ CNVs exist, that there is an overall
median CNV length of ~2.9 kb, and that 95% of CNVs are
less than 100 kb.66 These smaller CNVs were previously
undetectable because of technological limitations, and
CNV sizes from previous studies have often been overesti-
mated for the majority of CNVs.11,74 These recent studies
demonstrate that only 1%–2% of all CNVs in normal indi-
viduals are larger than 1Mb.11,66 A summary of recommen-
dations appears in Table 3 and in the Supplemental Data.
Impact of Balanced Rearrangements and Low-level
Mosaicism on Clinical Sensitivity of CMA
G-banded karyotyping is still important in the detection of
balanced rearrangements and low-level mosaicism, both of
which are not uniformly detectable by CMA. The clinical
sensitivity of CMA depends on the proportion ofrican Journal of Human Genetics 86, 749–764, May 14, 2010 755
Table 3. Recommendations for CMA Testing of Individuals with Unexplained Developmental Delay/Intellectual Disability, Autism
Spectrum Disorders, or Multiple Congenital Anomalies
Recommendation for CMA Platform:
1. CMA standards should not be speciﬁc to a particular array platform. Arrays based on BAC clones, long oligonucleotides or SNP-detecting shorter
oligonucleotides can achieve the recommended coverage and level of resolution.
Recommendations for CMA Coverage and Probe Density:
1. In order to perform the same intended purpose as a karyotype, CMA must have uniform coverage to detect all areas of imbalance at a resolution
exceeding that of a karyotype (~5 Mb). Currently, to detect CNV we recommend a resolution of R400 kb throughout the genome as a balance of
analytical and clinical sensitivity.
2. For oligonucleotide and SNP arrays, multiple consecutive probes are needed to permit a call to be made, so the array must be designed to include
sufﬁcient probe density for each targeted region. Note that SNP arrays may require a greater number of consecutive probes to permit a reliable call to be
made.
3. Laboratories that choose to add probes to cover Mendelian disease loci should explicitly state the minimum detectable imbalance and clinical
sensitivity of the assay for each disease at each locus and point out the availability of sequence-based technology for detecting mutations that are not
detectable by CMA.
Recommendations Related to Balanced Rearrangements, Low-Level Mosaicism, and Positive Family History of Known
Chromosomal Abnormalities or Reproductive Loss:
1. CMA can detect many more submicroscopic pathogenic genomic imbalances than the number of balanced rearrangements it would miss.
Cytogenetically balanced rearrangements and low-level mosaicism, which would not be detected by CMA, cause only a small proportion of all cases of
unexplained DD/ID, ASD, and/or MCA.
2. G-banded karyotyping should be offered to patients with a family history of a balanced chromosomal rearrangement, a history of multiple
miscarriages, or certain other conditions, as discussed.
Recommendations for a CMA Database:
1. CMA Database should be ‘‘platform neutral’’ and able to incorporate information based on chromosomal position according to the human genome
(hg) build.
2. All raw data should be freely accessible to all qualiﬁed researchers who register with dbGaP at NCBI.
3. Curated data should be publicly released on a quarterly basis and made available to major genomics resources and commercial vendors, as well as
individuals and clinical laboratories.potentially pathogenic balanced rearrangements, and
mosaic chromosomal material, in this patient population.
The available evidence suggests that (1) truly balanced re-
arrangements represent only a small proportion of clini-
cally signiﬁcant genomic events in this patient population
and (2) many ‘‘apparently balanced’’ rearrangements de-
tected by G-banding are not balanced at the DNA level.
Balanced rearrangements account for a minority of
cytogenetically detectable events in patients with ID.
G-banded karyotyping of large cohorts of individuals with
ID shows apparently balanced structural abnormalities in
1/500 patients, and in 1/2,000 patients, these occur de
novo.75 Balanced rearrangements make up only about
10% of cytogenetically visible abnormalities in patients
with ID, meaning that only about 0.3% of patients with
ID who are tested by karyotype analysis would have such
changes.1,54,76 In the general population, balanced rear-
rangements are also quite common. A study of 377,357
amniocenteses showed a de novo reciprocal translocation
in approximately 1/2,000 and a balanced Robertsonian
translocation in 1/9,000.77
Moreover, although cytogenetic events might appear
balanced at the microscopic level of resolution, many
have a submicroscopic imbalance, especially among indi-
viduals with an abnormal phenotype.78,79 In one study of
ten patients with abnormal phenotypes and chromosomal756 The American Journal of Human Genetics 86, 749–764, May 14,rearrangements that appeared balanced by conventional
cytogenetic methods, six had submicroscopic imbalance
according to CMAwith 1Mb resolution.78 In a larger study
of 59 patients with apparently balanced rearrangements
(41 de novo reciprocal translocations and 18 de novo
complex chromosomal rearrangements), 27 patients were
found to have an abnormal phenotype attributed to the
chromosomal rearrangement itself. Analysis of these 27
patients with higher-resolution oligonucleotide arrays
(Agilent 44k and 244k) revealed a submicroscopic imbal-
ance in 11/27 patients, or 41%.79 A more recent study of
14patientswith anapparently balanced chromosomal rear-
rangement revealed a submicroscopic imbalance in 4/14
patients, or 29%.80
Another approach to this question is to consider the
impact of balanced translocations on phenotypically
normal individuals. Most apparently balanced reciprocal
translocations in phenotypically normal individuals do
not contain genomic imbalance.81 Among balanced rear-
rangements that interrupt a gene, approximately half
(16/31) are found in healthy individuals.80 In the setting
of multiple miscarriages, a balanced translocation in one
of the parents could be the explanation for unbalanced
offspring, and G-banded karyotyping should still be the
standard of care for this indication. In some cases, family
history can be a clue to segregation of a balanced2010
translocation. In clinical settings, probands are more likely
to carry an imbalance, and parents and other family
members would subsequently be tested by traditional cyto-
genetic methods.
The incidence of low-level mosaicism is relatively low
compared to the incidence of other detectable chromo-
somal imbalances in this patient population. Conlin
et al. (2010) observed mosaic aneuploidy in 1% of 2,019
patients with a variety of diagnoses (the most common
diagnosis was DD),82 and G-banded karyotyping of a stan-
dard 20 cells is estimated to detect suchmosaicism at a level
of 14%.83 Detection of mosaicism as low as 10% is possible
with BAC-based arrays,27 but the trend among laboratories
is for increasing use of oligonucleotide arrays. Although
similar validation studies are needed for long-oligo-based
arrays, clinical experience indicates that mosaicism for
segmental aneuploidy is detectable to a level of about
20%–30%mosaic cells with most current platforms.84 SNP
arrays can detect lower levels of mosaicism (below 5% in
some cases) because of the increased resolution afforded
by genotyping in conjunction with probe intensity.82
Many types of mosaicism are missed by karyotyping either
because they are not present in the relevant lymphocytes or
because the cells with the imbalance are unable to respond
to the mitogen.27,85,86 Regardless of the method, ease of
detectionwill be proportional to the size ofmosaic chromo-
some fragments. At this time, CMA performs comparably
to G-banded karyotyping for detection of mosaicism.
Development of an Open-Access CMA Database
Difﬁculties interpreting VOUS can be overcome with the
cooperation of researchers, clinicians, clinical laboratory
directors, and bioinformaticians.
The most comprehensive existing online database for
presumed benign CNVs is DGV, but this valuable resource
is based on testing of presumably healthy individuals and
does not provide clinical information. A recently launched
database of structural variation from both normal control
populations and disease populations is dbVAR, developed
and housed at NCBI within the NIH. Correlation of clinical
phenotypes with speciﬁc genomic rearrangements requires
databases that include data from individuals with DD/ID
or MCA and is exempliﬁed by the interactive web-based
database DECIPHER, which incorporates a suite of tools de-
signed to aid in the interpretation of submicroscopic chro-
mosomal imbalances, inversions, and translocations.87
DECIPHER enables free public access to fully consented
molecular and phenotypic data as well as password-pro-
tected protocols for individual labs to securely upload
and manage patient information.
With more than 100 clinical CMA laboratories currently
participating in the ISCA Consortium, it can be anticipated
that this database will exceed several hundred thousand
CMA cases within the next 2–3 years. Data at the individual
level will be stored in a controlled-access environment in
dbGaP, and curated summary data, including CNV region
calls and phenotypic associations, will be available andThe Amevisualized throughvarious resources, including public data-
bases and individual vendor software. This large dataset, in
combination with DECIPHER, DGV, and dbVAR, should
substantially reduce the current frequency of VOUS results.
However, CNVs with incomplete penetrance and variable
expression will remain signiﬁcant challenges, particularly
in the prenatal setting, unless the molecular basis of the
phenotypic variation can be identiﬁed.Discussion
Clinical geneticists, pediatric neurologists, and develop-
mental pediatricians are increasingly ordering CMA to
obtain a genetic diagnosis for their patients with unex-
plainedDD/ID, ASD, andMCA. A speciﬁc genetic diagnosis
facilitates comprehensive medical care and accurate recur-
rence risk counseling for the family. Similar to our results,
a recent meta-analysis of CMA on 13,926 subjects with ID
and/orMCA,mostofwhomhadnormal conventional cyto-
genetic studies, reported an overall diagnostic rate of 10%
for pathogenic genomic imbalances.88 Another retrospec-
tive analysis of 36,325 patients with DD estimated that
a pathogenic abnormality could be detected in ~19% of
unselected DD/ID patients via genome-wide array-based
assays with a 30–70 kb median probe spacing.89
Our recommendation based on current evidence is to
offer CMA as the ﬁrst-tier genetic test, in place of G-banded
karyotype, for patients with unexplained DD/ID, ASD, or
MCA. Although others have proposed that CMA should
be considered a ﬁrst-tier test,63,89 this point of view is still
not widely accepted. Except in special cases, such as those
involving family history of multiple miscarriages, a karyo-
type is not cost effective in a child with DD/ID, ASD, or
MCA and a negative array study. CMA testing is not inex-
pensive, but the cost is less than the cost of a G-banded
karyotype plus a customized FISH test such as subtelomeric
FISH, and the yield is greater.
G-banding has been available formore than 38 years and
has the advantage of being a widely accepted and uniform
technique with an international system of cytogenetic
nomenclature (ISCN). By contrast, CMA is new and more
diverse in termsof techniques used, coverage, andapproach
to data interpretation. Overcoming this lack of uniformity
will allow clinicians to leverage the increased sensitivity
and speciﬁcity of CMA with genome-wide coverage to
detect genomic imbalances at higher resolution and with
less subjectivity in clinical settings. In addition, the more
precise delineation of deletions and duplications provides
direct links to the genome content in these areas, allowing
recognition of disease-causing genes.
CMA offers additional advantages beyond the ability
to detect submicroscopic genomic imbalances. Although
G-banding is better at detecting a small marker chromo-
some that contains exclusively pericentromeric repeat
sequences, the clinical signiﬁcance of such an event is
negligible, and CMA is better than traditional cytogeneticrican Journal of Human Genetics 86, 749–764, May 14, 2010 757
Figure 3. Algorithm for CMA Testing in Patients with Unexplained DD, MR, MCA, and ASD
This algorithm assumes that the patient does not present with features of a recognizable syndrome or metabolic disorder or that tests
have been negative for a suspected disorder. The ﬁrst-tier test is a chromosomal copy-number array or CMA. If no copy-number changes
are identiﬁed, or if only known CNVs that are known to be benign are identiﬁed, this testing is considered ‘‘normal’’ (left side of ﬁgure),
and further clinical evaluation is warranted to determine whether other testing should be pursued on the basis of the clinical presenta-
tion. If a CNV is detected within a known, clinically relevant region or gene, or if the CNV is in the genomic backbone and meets rec-
ommended size and gene content guidelines, then the result is considered a pathogenic CNV and ‘‘abnormal’’ (right side of ﬁgure). For
these cases, follow-up analyses include conﬁrmation studies and determination of the mechanism of imbalance in the proband and
parental analysis to determine recurrence risk. All other results are considered VOUS until parental analysis is performed to aid in the
ﬁnal clinical interpretation. After the parental analyses of ‘‘abnormal’’ and ‘‘VOUS’’ results, ﬁnal results may be classiﬁed into threemajor
categories: familial variant, abnormal with a low recurrence risk (RR), or abnormal with an increased RR. In addition, the ﬁnal interpre-
tation may remain VOUS in some instances, even after parental testing.techniques for identifying the composition of smallmarker
chromosomes when they contain sufﬁcient euchromatic
material.90 CMA is also superior to FISH for detecting sub-
microscopic duplications because of its higher resolution
(multiple small oligonucleotide probes can recapitulate
the coverage of a single BACprobe) and because of the tech-
nical difﬁculty of visualizing tandem duplications bymeta-
phase FISHanalysis.26Clinically signiﬁcant submicroscopic
duplications, including the reciprocal duplicationofknown
microdeletion syndromes such as the 7q11 Williams-
Beuren syndrome region91 or the 17p11.2 Potocki-Lupski
syndrome region,92 are more easily identiﬁed by CMA.
The ISCA Consortium proposes the clinical algorithm in
Figure 3 to guide postnatal testing in this patient popula-
tion. For clinical testing, traditional cytogenetic methods,
such as FISH, might offer the best conﬁrmation for certain
abnormal ﬁndings. For example, terminal deletions or
duplications are more likely than interstitial events to be758 The American Journal of Human Genetics 86, 749–764, May 14,involved in a rearrangement, especially when more than
one deletion or duplication is identiﬁed in a single indi-
vidual. Some labs might use other methods, such as quan-
titative PCR (qPCR) and multiplex ligation and probe
ampliﬁcation (MLPA). The need for conﬁrmatory testing
purely for copy-number determination is debatable in
cases such as those involving very large deletions or dupli-
cations (typically involving dozens of consecutive probes).
In general, traditional cytogenetic methods are still
needed for single-cell analysis. Other circumstances in
which traditional cytogenetic methods are indicated
instead of (or at least before) CMA includewhen the patient
has a recognizable chromosomal syndrome such as trisomy
21, trisomy 13, Turner syndrome, or Klinefelter syndrome.
For these circumstances, conventional cytogenetic analysis
or interphase FISH analysis might provide a more rapid
turn-around time, allow more sensitive detection of
low-level mosaicism, and provide information regarding2010
position to distinguish free trisomy from translocation-
associated trisomy. For couples with a history of recurrent
miscarriage or other signiﬁcant family history of reproduc-
tive loss, conventional chromosome analysis to identify
potential balanced translocations would still be the most
appropriate ﬁrst-tier test.
Somemight consider FISH follow-up testing to be impor-
tant for detection of possible insertional translocations
(IT). These events are rare at the karyotypic level; they
occur in approximately 1:80,000 live births.93 IT might
be more common at the submicroscopic level, but speciﬁc
incidence rates have not been published. The potential
implications of IT for genetic counseling about recurrence
risk are one argument in favor of FISH testing after identi-
ﬁcation of a copy-number gain by CMA. Other evidence
suggests that parental testing is best done by CMA because
breakpoints may be unstable on transmission.94 However,
on the basis of limited published studies95 and clinical
experience, most CNVs have similar, if not identical,
breakpoints between parent and child.
CMA testing of this patient population must provide
whole-genome coverage in order to replace a karyotype,
as outlined above. Clinical labs might increasingly utilize
custom arrays to detect intragenic deletions and duplica-
tions in individual genes associated with Mendelian disor-
ders, and we agree that ﬁrst-tier clinical testing for most
Mendelian disorders should be based on sequencing and/
or platforms, such as custom arrays, with high resolution
for small intragenic deletions. For CMA with resolution
of ~400 kb, as proposed here, information about ‘‘targeted’’
Mendelian genes should clearly state that CMA is intended
to detect large deletions or duplications that include part,
or all, of the targeted gene but that it is not intended to
replace complete gene sequencing or high-resolution array.
We acknowledge that concerns about identiﬁcation of
VOUS might also cause hesitation about adoption of CMA
as a ﬁrst-tier test, but we argue that this issue can be
adequately addressed through (1) choosing a level of resolu-
tion that balances sensitivity and speciﬁcity; (2) increased
data sharing through the established database; and (3)
parental studies to determine whether CNVs are de novo
or inherited (Figure 3). The fact that no single CMA plat-
form has been found to be clearly superior to all of the
others for clinical purposes and the absence of published
clinical standards for coverage and resolution have led to
a lack of uniformity in arrays offered in different laborato-
ries. The variety of available tests with nonoverlapping lists
of coveredgenomic regions is apotential barrier to thewide-
spread adoptionofCMAas theﬁrst-tier cytogenetic test, but
our recommendations (summarized in Table 3 and the
Supplemental Data) address this issue.
Even for arrays that contain comparable genomic
content, accurate interpretation of test results requires
increased sharing of primary data among clinical laborato-
ries so that benign copy-number variants can be distin-
guished from pathogenic ones. New recommendations
for CMA nomenclature outlined in ISCN 2009 shouldThe Amefacilitate interlaboratory comparisons of copy-number
changes, but they do not address the interpretation of clin-
ical signiﬁcance.96 Clinical utility will be improved
through a standard approach to interpretation of copy-
number variation applicable to all technology platforms,
and especially through efforts such as the widely accessible
ISCA database of pathogenic and benign copy-number
changes for comparison of clinical interpretations.
Performing largenumbers of parental samples is costly by
anymethod (CMA, FISH,.MLPA, or qPCR), but the need for
parental testingwilldiminishwithaccumulatingdataabout
benign CNVs. Population studies suggest that >99% of all
benign CNVs are inherited, and the vast majority of in-
herited CNVs aremuch smaller than 500 kb.95 Most patho-
genic copy-number alterations are larger than 1 Mb, and
most occur de novo. Inherited CNVs, such as those seen
in 1q21.1 (MIM 612474 and 612475),97 1q41q42,98 3q29
(MIM 609425 and 611936),99 15q11.2,100 15q13.2q13.3
(MIM 612001),101–103 16p11.2 (MIM 611913),70–72
16p13.11,100,103 and22q11.2 (MIM188400and608363),104
can also be pathogenic, but they have incomplete pene-
trance and variable expressivity. Variable clinical implica-
tions also result frommechanisms of inheritance that inﬂu-
ence the expressionof a trait, for examplewhenan inherited
deletion uncovers an imprinted region or a pathogenic
recessive allele on a homologous chromosome.105–107
Most genomic copy-number changes associated with
DD/ID are sporadic, but others can be inherited with
a recurrence risk as high as 50%. More highly penetrant
syndromes may be more easily recognized through history
and clinical exam, but such syndromes are more likely to
occur because of de novo changes that confer minimal
recurrence risk. Thus, syndromes exhibiting nonpene-
trance in some individuals can be more challenging to
diagnose, and the cost to the family for failure to diagnose
might be higher because there might be more inherited
variants for these types of syndromes and thus a signiﬁcant
recurrence risk. In general, VOUS within the resolution of
CMA should be reported so that they can be interpreted
clinically as the ﬁeld advances.
An extensive discussion of ethical and legal issues associ-
ated with advances in CMA technology is beyond the
scope of the current manuscript. Brief examples include
the ability of SNP arrays to identify unsuspected consan-
guinity that might point to an autosomal-recessive disease.
In some cases, the degree of consanguinity revealedmay be
indicative of parent-child incest, and there are potential
ethical and legal implications of reporting of such results.
Whole-genome analysis also raises important questions
regarding intellectual-property issues around gene patents,
leading some institutions to instruct their CMA laborato-
ries to omit or mask coverage of such patented genes, to
the detriment of patient care. Current legal challenges to
gene patenting in the United States might alleviate this
particular concern.
As a community of clinical and laboratory geneticists, we
have anopportunity to increase the uniformity ofCMAandrican Journal of Human Genetics 86, 749–764, May 14, 2010 759
its clinical interpretation in laboratories around the world.
Clinical geneticists have always worked closely with
genetics laboratories to interpret results in the context of
the patient’s clinical ﬁndings. In this regard, clinical genet-
icists must have or develop a basic understanding of CMA,
including indications for testing, interpretation of results,
and counseling of families. As more medical specialists
utilize this technology, clinical and laboratory geneticists
will play an important role inhelping these specialists inter-
pret the tests and communicate results to the families.
Educational tools should be developed and utilized in
the setting of ongoing continuing medical education for
individuals in practice as well as for those in laboratory
and clinical training programs.
Supplemental Data
Supplemental Data include general recommendations of the ISCA
Consortium.
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